Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.

Slides:

Advertisements

Similar presentations

Long-term outcome of patients in the LNH-98

Advertisements

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de.

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma by René-Olivier Casasnovas,

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses by Alain H. Rook, Gary S. Wood, Elisa K. Yoo,

Suboptimal dosing of rituximab in male and female patients with DLBCL

Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy.

Severe human herpesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody by Olivier Thaunat,

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

by James O. Armitage, and Dan L. Longo

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease by Marijke R. Canninga-van Dijk, Hanneke.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat elderly patients with myeloma

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 by Christoph Schliemann, Alessandro.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States by Jeffrey I. Cohen, Elaine S. Jaffe,

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

by Fangxin Hong, Thomas M Habermann, Leo I

Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

CME-Certified 2012 Hematology Tumor Board Series: Practical Solutions to Current Clinical Challenges in B-Cell Lymphoma.

Primary testicular lymphoma

Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas by Antonino Carbone, Annunziata Gloghini,

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.

Lymphoma spread? Target CD47-SIRPα!

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

How I treat refractory CLL

Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B–severe combined immune deficiency or Omenn.

by George Z. Rassidakis, Mauricio P. Oyarzo, and L. Jeffrey Medeiros

Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma by Chrystelle Guiter, Isabelle Dusanter-Fourt, Christiane Copie-Bergman, Marie-Laure.

Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia.

Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens Christopher D. Carey, Daniel.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

by Wendy Lim, Sara K. Vesely, and James N. George

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy by Wyndham H. Wilson, Michael L. Grossbard,

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping by Christian Hoffmann, Markus.

PD-L1 and tumor-associated macrophages in de novo DLBCL

Histopathology and bcl-2 immunohistochemistry of in situ follicular lymphoma.(A-B) Low-power view of H&E-stained (A) and bcl-2–stained (B) sections showing.

by Matthew S. Painschab, Kate D

Resistance mechanism for ibrutinib in marginal zone lymphoma

by Pierre Sesques, and Nathalie A. Johnson

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

How I treat early-relapsing follicular lymphoma

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Evaluation of clinical responses after infusion of CART19 cells

Follicular Lymphoma International Prognostic Index

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

Optimizing therapy for nodal marginal zone lymphoma

Presentation transcript:

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas Mounier, Josette Briere, Christian Gisselbrecht, Jean-Francois Emile, Pierre Lederlin, Catherine Sebban, Francoise Berger, Andre Bosly, Pierre Morel, Herve Tilly, Reda Bouabdallah, Felix Reyes, Philippe Gaulard, and Bertrand Coiffier Blood Volume 101(11):4279-4284 June 1, 2003 ©2003 by American Society of Hematology

The bcl-2 staining patterns. The bcl-2 staining patterns. The bcl-2 staining patterns for a nodal biopsy specimen (immunoperoxidase method and monoclonal antibody bcl-2). (A) A few positive T cells as positive control (arrows). Tumor cells × 537) are bcl-2–. (B) Almost all tumor cells × 537) are strongly positive for bcl-2 protein expression. Nicolas Mounier et al. Blood 2003;101:4279-4284 ©2003 by American Society of Hematology

OS according to treatment and bcl-2 protein expression. OS according to treatment and bcl-2 protein expression. (A) OS for patients treated with CHOP. (B) OS for patients treated with R-CHOP. Black lines indicate bcl-2– patients and gray lines indicate bcl-2+ patients. Nicolas Mounier et al. Blood 2003;101:4279-4284 ©2003 by American Society of Hematology

OS according to bcl-2 protein expression and treatment. OS according to bcl-2 protein expression and treatment. (A) bcl-2– patients. (B) bcl-2+ patients. Black lines indicate patients treated with CHOP and gray lines indicate patients treated with R-CHOP. Nicolas Mounier et al. Blood 2003;101:4279-4284 ©2003 by American Society of Hematology

OS according to aa-IPI and bcl-2 protein expression and treatment. . Nicolas Mounier et al. Blood 2003;101:4279-4284 ©2003 by American Society of Hematology